Kartrider: Drift’s Preseason Brings Arcade Thrills to Kart Racing Fans on PC and Mobile Platforms
12.1.2023 07:16:00 EET | Business Wire | Press release
Starting today, KartRider: Drift , Nexon’s highly anticipated free-to-play kart racing party game, is available to download and play on PC and mobile platforms via Steam, Nexon Launcher, iOS App Store, and Google Play.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111006031/en/
KartRider: Drift from Nexon America now available on Steam, iOS, and Android (Graphic: Business Wire)
During Preseason, racers can test their mettle on bright, colorful tracks against PC and mobile racers from around the globe, rendered in stunning Unreal® Engine 4 graphics.
With unique characters and karts, racers have complete control over customization options to express themselves fully and cross the finish line in style! More characters, karts, accessories, and emotes can be unlocked via the Racing Pass, where racers can complete different daily challenges and event challenges. Premium challenges are also available with the purchase of a Premium Racing Pass.
Racers are trained and challenged through a unique License System in a series of meticulously designed courses. In Time Attack Mode, racers can then test their skills to top the leaderboards.
KartRider: Drift brings the deep kart customization that PC and mobile players expect, while delivering arcade-quality racing thrills to casual and seasoned players alike. Now’s the time for players to put the pedal to the metal – download KartRider: Drift and burn rubber!
NOTE FOR EDITORS:
KartRider: Drift’s Preseason launch on January 11 is only for PC (Steam, Nexon Launcher) and mobile (iOS, Android) players.
Playstation and Xbox console players will be able to join PC and mobile racers beginning with Season 1 (S1 launch to be announced at a later date).
Nexon’s KartRider Rush+ mobile racing game, launched in 2020, will continue to operate as a standalone title and does not share cross-play with KartRider: Drift.
Social Media: Twitch / Twitter / Instagram / Discord / Facebook / YouTube
About
Kartrider: Drift
KartRider: Drift is Nexon’s new multiplayer kart racing party game, taking inspiration from earlier titles in the KartRider franchise, delivering drift-fueled racing action and featuring multiple game modes and deep kart and character customization in stunning Unreal® Engine 4 graphics. Available on Steam, the Nexon Launcher, mobile (iOS and Android) during Preseason, and with Xbox and PlayStation consoles joining at the launch of Season 1, KartRider: Drift
offers free-to-play, online cross-platform play and progression to challenge friends regardless of the platform they choose.
Launched in 2004, the original KartRider was the first title in Nexon’s legendary kart racing series, and subsequently gained huge popularity in Asia and beyond, amassing more than 380 million players during the nineteen years since release. As a franchise, KartRider has established a strong brand across Asian markets and a huge eSports presence in Asia, with an official league starting in 2005. It continues to be the longest-running eSports league to date.
About
Nexon America Inc.
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111006031/en/
Contact information
North America
and LATAM
Brian Klotz, Nexon America
NA_pr@nexon.com
Europe and UK
Heaven Media
nexon@heavenmedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release
The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom